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Alzheimer’s disease (AD) is one of mankind’s greatest afflic-
tions. It is the most common degenerative illness of the human 
nervous system and the leading form of dementia worldwide. 
Almost unknown to the community 40 years ago, AD affects 
approximately 1%–2% of the world’s population, with ageing 
the highest risk factor. The neuropathological features of AD 
are mainly intracellular neurofibrillary tangles (NFTs) con-
sisting of hyperphosphorylated tau protein and extracellular 
amyloid beta (Aβ) plaques (Mandelkow & Mandelkow, 1998; 
Serrano- Pozo, Frosch, Masliah, & Hyman, 2011). However, 
the best correlate with clinical dementia is the characteris-
tic neuronal and synaptic loss (DeKosky, Scheff, & Styren, 
1996; Masliah & Terry, 1993; Scheff, Price, Schmitt, & 
Mufson, 2006; Terry et al., 1991).
Alzheimer’s disease has numerous risk factors, approxi-
mately 70% of which are genetic and 30% have an environ-
mental background (Dorszewska, Prendecki, Oczkowska, 
Dezor, & Kozubski, 2016). Rare, dominant mutations that 
cause familial AD are located either within the amyloid 
precursor protein (APP) or within one of the APP cleaving 
enzymes, such as presenilin 1 and 2 (PSEN1 and PSEN2). 
Based on these observations, Hardy & Allsop postulated 
that the primary events in AD pathogenesis are increased Aβ 
load as a consequence of altered APP metabolism and that 
tau phosphorylation and NFTs occur secondarily (Hardy & 
Allsop, 1991). This is known as the amyloid cascade hypoth-
esis, which was later modified and “corrected” to describe 
a shift towards APP cleavage into larger Aβ42 fragments, 
rather than Aβ40, leading to increased plaque deposition.
However, we still have large gaps in our knowledge of 
disease mechanisms and we still have no disease- modifying 
treatments. To increase our understanding of the disease, gen-
erate novel therapeutic strategies and ultimately help patients 
suffering from dementia, a new research unit was founded in 
2016: the UK Dementia Research Institute (DRI). The Medical 
Research Council (MRC), Alzheimer’s Society and Alzheimer’s 
Research UK invested £250 million to help the UK DRI break 
new ground by bringing together world- leading expertise in 
biomedical, care and translational dementia research.
Prof. Bart de Strooper is the head of the UK DRI and re-
cently gave a plenary talk at the FENS- Kavli Winter Meeting 
(5 December–8 December 2017) at the Institute of Science 
and Technology in Klosterneuburg, Austria. He opened the 
talk by highlighting Aβ as the culprit in AD pathogenesis, 
supported by the fact that all mutations in familial AD (causal 
genes) and many of the risk genes affect Aβ aggregation. 
More than 180 mutations have been found in the Aβ generat-
ing γ- secretases, PSEN1 & PSEN2, which historically made 
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This is a short report summarising the plenary talk by Professor Bart de Strooper, at the 
2017 FENS-Kavli winter symposium. We have tried to capture some of the key points 
in his lecture on dementia research and we discuss his vision for the new UK Dementia 
Research Institute (UK DRI). In his talk, Prof. de Strooper encourages us to focus on the 
multicellular influence on brain dysfunction in dementia and we summarise how the UK 
DRI is a timely and ambitious, collaborative endevour, aiming to conquer dementia.
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them promising and intensely studied targets for potentially 
reducing Aβ accumulation in brains of AD patients. However, 
PSEN- targeted drugs in phase III clinical trials failed to im-
prove cognitive function and failed to significantly reduce Aβ 
burden (Doody et al., 2013). Relatively late in these studies, 
it became clear that side effects further limited the clinical 
use of PSEN inhibitors (De Strooper, 2014).
The question we should ask is, why did the trials fail? Prof. 
de Strooper highlighted an important point during his talk 
which may help us understand this, namely that PSEN1 pos-
sesses conformational flexibility which is largely influenced 
by single nucleotide polymorphisms (SNPs) in the PSEN1 
gene (Bai, Rajendra, Yang, Shi, & Scheres, 2015). These SNPs 
cause a conformational change in the structure and activity 
of PSEN1; therefore, depending on the genetics of each AD 
patient, drugs targeting this enzyme will likely have differing 
effects. Moreover, PSEN1 does not possess a single nonsense 
mutation, meaning that all known PSEN1 mutations or SNPs 
likely alter PSEN1 function and in this way contribute to AD 
pathology and the patient’s response to PSEN1- targeted ther-
apeutics. For example, some of the PSEN1 mutations desta-
bilize the enzyme leading to the release of longer forms of 
Aβ (≥42) (Szaruga et al., 2015). Thus, Prof. de Strooper drew 
two conclusions, first, that qualitative changes in Aβ gener-
ation cause AD, and second, that these findings provide the 
theoretical basis for the development of γ- secretase/substrate 
stabilizing compounds for the treatment of AD.
When summarizing what the clinical mutations really 
teach us, Prof. de Strooper concluded that we should aim to 
(pharmacologically) stabilize the enzyme, we should target 
only one of the PSEN enzymes and not all four at once, we 
should be mindful of enzyme kinetics and last but not least, 
we should not give up the best- validated drug target for AD.
Despite these significant findings, Prof. de Strooper was 
cautious in describing malfunction of PSEN1 as causative 
for AD, suggesting that the numerous studies on AD ge-
netics provide powerful insights into pathomechanisms be-
yond PSEN1 failure. Special emphasis was put on changes 
in (phospho)lipid metabolism and microglial dysfunction. 
Bridging these findings, recent AD research has shown more 
and more clearly that AD is a chronic multicellular disorder 
and not solely a breakdown of neurons and synapses. The am-
yloid hypothesis has been refined over the last 25 years, but 
still falls short of fully explaining AD pathogenesis (Karran 
& De Strooper, 2016). Whilst some genetic studies highlight 
the role of Aβ42 in disease pathogenesis, the neuron- centric 
view and the linearity of the cascade remain under debate 
(De Strooper & Karran, 2016). Furthermore, many of the ge-
netic risk factors involve genes highly expressed in glial cells 
rather than neurons (Karch & Goate, 2015). Taken together, 
there is an urgent need to increase our understanding of the 
multicellular aspects of AD and discover the roles glial cells 
undoubtedly play in AD pathogenesis.
The question Prof. de Strooper raised was how to design 
good quality experiments to examine the multicellular shape 
of AD. He suggested using an APP mouse model, presenting 
both Aβ plaque deposition and glial activation. He described 
the APP knock- in model, which harbours the Swedish, the 
Iberian/Beyreuther and the Arctic mutations in the human-
ized endogenous mouse APP gene. These mice have no 
drawbacks of overexpression and therefore no aberrant accu-
mulation of other APP cleavage products. They also express 
APP under the endogenous promotor meaning it should be 
expressed in the right cells at the right time. Furthermore, this 
model shows progressive astro- and microgliosis in an age- 
dependent manner, thus merging important hallmarks of AD 
(Masuda et al., 2016; Saito et al., 2014). Using this mouse 
model, Prof. de Strooper’s group prepared cortex and hippo-
campus cell suspensions from C56/Bl6 and APPKI mice, iso-
lated 10,000 single microglia and analysed up to 3,000 genes 
at four different time points (3, 6, 12 and 21 months). By 
doing this, his team can identify genetic and protein changes 
in individual cell types, rather than in a whole brain homoge-
nate where all genes and proteins from all cells are combined 
into one sample. As Prof. de Strooper put it: “We want fruit, 
not smoothies.” The analysis of this exciting study is still on-
going but promises to reveal valuable insights into disease 
progression with a focus on the multicellular nature of AD.
Another important point to address is how human cells 
react in AD. Whilst it is currently beyond our technology to 
accurately study changes in the living human brain at the cel-
lular level, Prof. de Strooper has come up with a fascinating 
alternative. A study by Espuny- Camacho and Arranz et al. 
described transplanting iPSC- derived human neurons into an 
APP/PS1 mouse to develop a chimeric AD animal that con-
tains implanted human neurons. Analysing the human–mouse 
chimera, they noticed significant degeneration and loss of 
human neurons with significant tau pathology (although no 
tangle formation), which was absent when these neurons were 
injected into a wild- type mouse. A genomewide expression 
analysis of the reisolated human neurons showed upregula-
tion of genes involved in myelination and downregulation of 
genes related to memory and cognition, synaptic transmission 
and neuronal morphology (Espuny- Camacho et al., 2017).
This study suggests a clear non- cell- autonomous influ-
ence on human neuronal survival in the AD mouse brain. It 
would be interesting to know how other human cells would 
react to this implantation. For example, does the toxic envi-
ronment of the AD mouse brain lead to death or phenotypic 
change in implanted human microglia? These questions were 
raised by Prof. de Strooper and work is underway in his labo-
ratory to address them.
Given the emerging focus on AD as a non- cell- autonomous 
disorder, with influence from virtually all cell types in the brain, 
the UK DRI is incredibly well placed to significantly advance 
this area of research and reveal novel insights into disease 
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pathogenesis. The UK DRI will unite 400 researchers from six 
universities in three nations (England, Scotland and Wales) with 
a shared vision: addressing the cellular phase of dementia. The 
central UK DRI hub is based at University College London, 
with five DRI centres located in University of Cambridge, 
Cardiff University, University of Edinburgh, Imperial College 
London and King’s College London. Their mission is to rev-
olutionize dementia research by finding new ways to diagnose 
the disease, improve quality of life for patients and most ambi-
tiously of all, to prevent dementia. Prof. de Strooper wants to 
build on strong creativity and collaboration within and across 
DRI centres, leading to international excellence and recogni-
tion. The UK DRI will also facilitate international collabora-
tions. Of note, UK DRI researchers already have collaborative 
publications with other FENS- Kavli Network of Excellence 
scholars examining synapse degeneration in dementia models 
(McInnes et al., 2018; Zhou et al., 2017).
The UK DRI centre at the University of Edinburgh focuses 
on this question of multicellular influence on AD progres-
sion, highlighting the interplay between several cell types in 
the brain leading to neuron loss. As part of the research team 
in Edinburgh, we will investigate the complex interaction be-
tween neurons, glial cells and blood vessels, thereby creating 
a holistic approach to address the cellular phase of AD in 
order to pave the way for future clinical trials.
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